RELMADA THERAPEUTICS, INC. Cost, Direct Tax and License
RELMADA THERAPEUTICS, INC. (RLMD) reported Cost, Direct Tax and License of $180.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DirectTaxesAndLicensesCosts · last filed 2023-08-08
- RELMADA THERAPEUTICS, INC. cost, direct tax and license for the quarter ending 2023-03-31 was $180.00K.
- RELMADA THERAPEUTICS, INC. cost, direct tax and license for fiscal 2018 was $16.60K.
- RELMADA THERAPEUTICS, INC. cost, direct tax and license for fiscal 2015 was $16.60K.
| Period end | Cost, Direct Tax and License 0 month | Cost, Direct Tax and License 1 month | Cost, Direct Tax and License 3 month | Cost, Direct Tax and License 12 month |
|---|---|---|---|---|
| 2023-03-31 | $180.00K 10-Q · filed 2023-05-11 | |||
| 2018-06-30 | $16.60K 10-K · filed 2018-09-28 | |||
| 2017-06-08 | $7.53K 10-Q · filed 2023-08-08 | |||
| 2015-06-30 | $16.60K 10-K · filed 2021-03-24 | $16.60K 10-KT · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |